WAVEMAN · COMPANY

TRLV · Trulieve Cannabis Corp.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

TRLV

Name: Trulieve Cannabis Corp. (TRLV) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Trulieve Cannabis Corp.

PHARMA & BIOTECH · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · CIK 0001754195

SEC FILINGS☆ WATCH

INSIDER NET · 180D

-$14.7M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

121

13F, latest reported quarter

REVENUE GROWTH

-0.4%

XBRL, annual

NET MARGIN

-10.3%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$14.7M over 180 days

-$14.7M over 90 days · -$14.7M of it by a 10%+ holder

below 87% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

121 funds added or opened last quarter

more than 73% of Pharma & Biotech

REVENUE

-0.4% year over year

below 57% of Pharma & Biotech

MARGIN

-10.3% net margin

more than 55% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

121 funds added or opened positions in the latest 13F quarter, of 125 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +47.5%

+47.5%12M

INSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows a net $14.7M sold by insiders over 180 days, 121 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Trulieve Cannabis Corp. insiders sold a net $14.7M of stock across 7 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Rivers Kim A.

Chairman and CEO

SELL

2026-06-26

136,811.0

$1.2M

Rivers Kim A.

Chairman and CEO

SELL

2026-06-25

300,000.0

$2.5M

Rivers Kim A.

Chairman and CEO

SELL

2026-06-24

400,000.0

$3.3M

Rivers Kim A.

Chairman and CEO

SELL

2026-06-23

380,000.0

$3.2M

Rivers Kim A.

Chairman and CEO

SELL

2026-06-22

204,815.0

$1.9M

7 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 2 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

AdvisorShares Investments LLC

10,641,152.0 sh

$104.6M

CANTOR FITZGERALD, L. P.

7,500,000.0 sh

$73.7M

NOMURA HOLDINGS INC

5,065,849.0 sh

$49.8M

Marex Group Ltd

3,250,000.0 sh

$31.9M

ING GROEP NV

2,665,000.0 sh

$26.2M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Executive pay vs shareholder return · Kim Rivers

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$7.6M

$11.7M

$879.9K

-73%

2024

$5.1M

$3.5M

$1.6M

-84%

-78%

2023

$3.4M

$3.8M

$682.3K

-84%

-64%

2022

$3.9M

-$656.2K

$1.4M

-76%

-67%

2021

$8.1M

$7.1M

$2.1M

-18%

-21%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$1.2B	$1.2B	$1.1B	$1.2B
GROSS PROFIT	$711.2M	$715.7M	$588.6M	$689.1M
OPERATING INCOME	$143.5M	$97.8M	$-221.6M	$50.2M
NET INCOME	$-116.4M	$-155.1M	$-526.8M	$-246.1M
EPS (DILUTED)	-0.58	-0.79	-2.28	-0.95
OPERATING CASH FLOW	$272.8M	$271.5M	$201.8M	$23.1M
CASH	$255.5M	$238.8M	$201.4M	$207.2M
LONG-TERM DEBT	$136.7M	$364.8M	$363.2M	$541.7M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE